Table 2 Associations of clinicopathological parameters with pCR in breast cancer patients
Variables | N-pCR | pCR (N, %) | P-value |
|---|---|---|---|
Age (years) | |||
  < 48 | 84 | 24 (22.22) | 0.419 |
  ≥ 48 | 109 | 24 (18.05) |  |
Body mass index (kg/m2) | |||
  < 24 | 94 | 31 (24.80) | 0.049 |
  ≥ 24 | 99 | 17 (14.66) |  |
Clinical T stage | |||
 T1 | 16 | 10 (38.46) | 0.043 |
 T2 | 137 | 29 (17.47) |  |
 T3-T4 | 40 | 9 (18.37) |  |
Clinical N stage | |||
 N0 | 47 | 37 (44.05) | 0.000 |
 N1–N3 | 146 | 11 (7.01) |  |
Grade | |||
 Grade1 | 2 | 1 (33.33) | 0.013 |
 Grade2 | 104 | 16 (13.33) |  |
 Grade3 | 56 | 14 (20.00) |  |
 UN | 31 | 17 (35.41) |  |
Phenotype by IHC | |||
 HR-positive | 85 | 16 (15.84) | 0.042 |
 HER-2-positive | 72 | 15 (17.24) |  |
 Triple-negative | 36 | 17 (32.07) |  |
Ki67 proliferation index | |||
  ≤ 20 | 59 | 10 (14.49) | 0.182 |
  > 20 | 134 | 38 (22.09) |  |
Nac regimens | |||
 Anthra based | 29 | 10 (25.64) | 0.291 |
 Tax based | 18 | 7 (28.00) |  |
 Anthra + Tax based | 146 | 31 (17.51) |  |
SIRI | |||
  < 0.72 | 37 | 26 (41.27) | 0.000 |
  ≥ 0.72 | 156 | 22 (12.36) |  |
NLR | |||
  < 1.77 | 9 | 19 (67.86) | 0.000 |
  ≥ 1.77 | 184 | 29 (13.62) |  |
LMR | |||
  < 5.38 | 168 | 33 (16.41) | 0.002 |
  ≥ 5.38 | 25 | 15 (37.50) |  |
ALC | |||
  < 1.57 | 109 | 23 (21.10) | 0.286 |
  ≥ 1.57 | 84 | 25 (22.94) |  |